5-HT3 Receptor Antagonist and Respiratory Drive in Patients With ARDS
Status:
Not yet recruiting
Trial end date:
2023-05-06
Target enrollment:
Participant gender:
Summary
This is a pilot study aimed at acquiring primary physiological data, describing and
estimating the effects of a 5-HT3 receptor antagonist (ondansetron) on respiratory drive in
patients with acute respiratory distress syndrome (ARDS). The results of this study will
determine the interest and feasibility of assessing the clinical applications of ondansetron
in reducing patient self-inflicted lung injury (P-SILI) in ARDS, in subsequent studies.